Forma

Forma Therapeutics

This company develops medicines for patients with sickle cell disease and rare blood disorders.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.

Disc Medicine

This biopharmaceutical company develops novel therapeutic candidates to treat patients suffering from serious haematologic diseases by targeting red blood cell biology and iron homeostasis.

Pharmacyclics

This company develops small-molecule medicines for patients with cancer and immune-mediated diseases.

IMMvention Therapeutics

This biotechnology firm develops small molecule oral therapies for patients with sickle cell disease and other inflammatory or neurodegenerative conditions.

Bluebird Bio

This company develops and manufactures gene therapies for patients with severe genetic diseases, including sickle cell disease and beta-thalassaemia.

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.